Search Results
Apr 29, 2026, 10:15 ET A Supply Crisis Is Brewing in the Metals That Power Everything
intercepts reported across the program."We are excited to report the third batch of drill results from the Langis 2026 drill program," said Gary R. Thompson, Chairman and CEO of Brixton Metals. "These results are extraordinary and are among the most significant silver drilled intercepts known
More news about: USA News Group
Apr 29, 2026, 10:14 ET Vaimo and Go Autonomous announce strategic partnership to revolutionize B2B commerce
https://news.cision.com/vaimo/r/vaimo-and-go-autonomous-announce-strategic-partnership-to-revolutionize-b2b-commerce,c4342269The following files are available for download:
More news about: Vaimo
Apr 29, 2026, 10:12 ET Vaimo and Go Autonomous announce strategic partnership to revolutionize B2B commerce
https://news.cision.com/vaimo/r/vaimo-and-go-autonomous-announce-strategic-partnership-to-revolutionize-b2b-commerce,c4342269The following files are available for download:
More news about: Vaimo
Apr 29, 2026, 10:12 ET Norgine gibt die Marktzulassung der Europäischen Kommission für XOLREMDI® (Mavorixafor) bekannt, die erste zugelassene Behandlung für Patienten mit WHIM-Syndrom in der Europäischen Union
https://rarediseases.org/rare-diseases/whim-syndrome/. Zugriff im April 20263. Badolato R, Alsina L, Azar A, et al. Eine randomisierte Phase-3-Studie mit Mavorixafor, einem CXCR4-Antagonisten, bei WHIM-Syndrom. Blut. 2024;144(1):35-454. XOLREMDI
More news about: Norgine B.V.
Apr 29, 2026, 10:12 ET Europe Laboratory Information System (LIS) Market to Surpass USD 689.05 Million by 2031 - Exclusive Insights by Arizton
five players accounting for around 40%–45% of the total market share.Leading vendors are increasingly focusing on product innovation and R&D investments, particularly in AI integration, digital pathology, and cloud-enabled LIS platforms.Electronic health record (EHR) providers are
More news about: Arizton Advisory & Intelligence
Apr 29, 2026, 10:09 ET Handy & Handy Welcomes Associate Attorney Ashley R. Koford
Ashley R. Koford has joined the firm as an Associate Attorney, further strengthening our commitment to exceptional personal injury representation.
More news about: Handy & Handy
Apr 29, 2026, 10:07 ET 썬더소프트, 아쿠아드라이브 AIOS 2.1 출시로 SDV에서 AI 정의 차량으로의 업계 전환 선도
우수성으로 2026 iF 디자인 어워드(2026 iF Design Award)를 수상했다.썬더소프트 소개 썬더소프트(SZ: 300496)는 지능형 운영체제 제품 및 기술의 세계적 선도 제공업체다. 14개국에 걸친 글로벌 R&D 네트워크를 통해 썬더소프트는 자동차, AIoT, 로봇 공학, 스마트 산업 부문에 걸친 AIOS 및 엣지 지능 솔루션을 통해 물리적 세계에 힘을 실어준다. 자세한 정보는
More news about: ThunderSoft
Apr 29, 2026, 10:04 ET Bioretec Ltd: Notification pursuant to Chapter 9, Section 10 of the Finnish Securities Markets Act (Sp-Rahastoyhtiö)
https://news.cision.com/bioretec/r/bioretec-ltd--notification-pursuant-to-chapter-9--section-10-of-the-finnish-securities-markets-act--,c4342352
More news about: Bioretec
Apr 29, 2026, 10:02 ET Bioretec Ltd: Notification pursuant to Chapter 9, Section 10 of the Finnish Securities Markets Act (Sp-Rahastoyhtiö)
https://news.cision.com/bioretec/r/bioretec-ltd--notification-pursuant-to-chapter-9--section-10-of-the-finnish-securities-markets-act--,c4342352
More news about: Bioretec
Apr 29, 2026, 10:02 ET Norgine annonce l'autorisation de mise sur le marché par la Commission européenne de XOLREMDI® (mavorixafor), premier traitement autorisé pour les patients atteints du syndrome WHIM dans l'Union européenne.
https://rarediseases.org/rare-diseases/whim-syndrome/. Consulté en avril 20263. Badolato R, Alsina L, Azar A, et al. Un essai randomisé de phase 3 du mavorixafor, un antagoniste du CXCR4, pour le syndrome WHIM. Sang. 2024;144(1):35-454.
More news about: Norgine B.V.
Apr 29, 2026, 10:00 ET European Commission (EC) Approves Henlius and Organon's POHERDY® (pertuzumab), the First Approved Biosimilar to PERJETA (pertuzumab) in Europe
European Commission (EC), reflecting its globally aligned R&D capabilities, quality systems, and manufacturing standards.Driven by innovation, Henlius has built a diversified, platform-based technology ecosystem through coordinated R&D efforts across Shanghai, the United States, and other
More news about: Henlius
Apr 29, 2026, 09:00 ET MaterialsZone Launches Maven, a Conversational AI Interface for its Enterprise Materials Platform
MaterialsZone, a materials informatics platform providing AI-Guided R&D for Materials Innovation, today announced the launch of Maven, a conversational AI interface powered by its Enterprise Materials Knowledge Center. Designed for R&D and production teams, Maven adds a powerful new capability to the
More news about: MaterialsZone
Apr 29, 2026, 09:00 ET TECO Expands into Southeast Asia Power Market with Subsidiary; TECOBAR Launches Penang Plant
and global markets.With smart manufacturing and automation aligned with net-zero trends, the plant focuses on the R&D and production of high-performance armored busway systems for AI data centers and high-performance computing. Its products are certified to international
More news about: TECO Electric & Machinery Co.
Apr 29, 2026, 08:51 ET STL delivers resilient FY'26 performance; AI Data Centre business emerges as key growth engine
Large enterprises collaborate with STL to build their future-ready digital infrastructure. STL's business goals are driven by customer-centricity, R&D and sustainability. Read more,
More news about: Sterlite Technologies Ltd. (STL)
Apr 29, 2026, 08:49 ET American Warrior Association Launches National Awareness Campaign for Moral Injury, Debuts "The Journey Unbound" Documentary Series
that fosters camaraderie, reflection, and spiritual renewal. Building on that foundation, R3 extends this mission to first responders through a proactive, structured approach to wellness.Developed by the AWA, R3 (Respond. Restore. Resolve.) is a department-embedded wellness and resilience framework
More news about: American Warrior Association
Apr 29, 2026, 08:45 ET MacGregor strengthens delivery partnership on 165T AHC crane with repeat order
https://news.cision.com/macgregor/r/macgregor-strengthens-delivery-partnership-on-165t-ahc-crane-with-repeat-order,c4341326The following files are available for download:
More news about: MacGregor
Apr 29, 2026, 08:30 ET Strengthen Readiness for a Potential SAS-to-R Shift in Data Analytics, Upcoming Webinar Hosted by Xtalks
In this free webinar, see how R can support a compliant, future-ready approach to clinical data analytics. Attendees will learn about governance and validation strategies for R in GxP environments. The featured speakers will share organizational considerations when transitioning analytic platforms.
More news about: Xtalks
Apr 29, 2026, 08:30 ET WuXi Biologics Releases 2025 Sustainability Report, Advancing Sustainable Growth and Improving Healthcare Access
worldwide.With over 13,000 employees in China, the United States, Ireland, Germany, and Singapore — including experts and scientists in biologics R&D and manufacturing, technology innovation, and operational excellence — WuXi Biologics leverages its technologies and expertise to deliver efficient,
More news about: WuXi Biologics
Apr 29, 2026, 08:30 ET Baird Medical Reports Full Year 2025 Financial Results and Provides Corporate Update
recognized as a non-cash expense.Research and Development Expenses increased to $20.1 million, from $6.2 million in 2024. The increase in R&D expense was primarily attributable to investment in product advancement, including both new hardware and software-based technologies and enhancements
More news about: BDMD
Apr 29, 2026, 08:29 ET Norgine announces European Commission Marketing Authorisation for XOLREMDI® (mavorixafor), the first authorised treatment for patients with WHIM syndrome in the European Union
https://rarediseases.org/rare-diseases/whim-syndrome/. Accessed April 20263. Badolato R, Alsina L, Azar A, et al. A phase 3 randomized trial of mavorixafor, a CXCR4 antagonist, for WHIM syndrome. Blood. 2024;144(1):35-454.
More news about: Norgine B.V.
Apr 29, 2026, 08:22 ET Norgine announces European Commission Marketing Authorisation for XOLREMDI® (mavorixafor), the first authorised treatment for patients with WHIM syndrome in the European Union
https://rarediseases.org/rare-diseases/whim-syndrome/. Accessed April 20263. Badolato R, Alsina L, Azar A, et al. A phase 3 randomized trial of mavorixafor, a CXCR4 antagonist, for WHIM syndrome. Blood. 2024;144(1):35-454.
More news about: Norgine B.V.
Apr 29, 2026, 08:10 ET Applications Now Open for Second Annual Blueberry Boost Accelerator, Seeking Next Generation of Blueberry Innovation
commercialize what's next, now by turning startup innovation into measurable business growth. Through their 'Build. Buy. Partner.' approach, they accelerate R&D, de-risk M&A, and rapidly validate new technologies in-market. VentureFuel helps organizations with end-to-end innovation engines that deliver
More news about: U.S. Highbush Blueberry Council
Apr 29, 2026, 08:07 ET J.S. Held Leads Ongoing Global Wind-Down of Katerra, Inc., One of the Largest Construction Bankruptcies on Record
/PRNewswire/ -- As the Katerra, Inc., Chapter 11 proceedings reach a milestone phase, global consulting firm J.S. Held, along with Plan Administrator Daniel R. Williams, CPA, CTP, shares an update on the wind-down of the multi-billion-dollar construction company. Katerra's 2021 bankruptcy filing stands as one
More news about: J.S. Held
Apr 29, 2026, 08:00 ET United Imaging Healthcare Releases 2025 Annual Report and Q1 2026 Results, Delivering Strong Growth with Accelerated Global Expansion
2025, United Imaging Healthcare continued to deepen its commitment to innovation, with annual R&D investment reaching RMB 2.62 billion, up 15.95% year-on-year. Leveraging sustained high-intensity R&D investment and its globally coordinated innovation network, the Company made significant progress
More news about: United Imaging Healthcare Co., Ltd.
Apr 29, 2026, 08:00 ET Citius Oncology Ships First International Order of LYMPHIR™ to Europe
diftitox‑cxdl)INDICATIONLYMPHIR is an IL2-receptor-directed cytotoxin indicated for the treatment of adult patients with r/r Stage I-III cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy.IMPORTANT SAFETY INFORMATION BOXED WARNING:
More news about: Citius Oncology, Inc.